BlueRock Therapeutics receives FDA RMAT designation for Parkinson’s disease cell therapy candidate bemdaneprocel

Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson’s disease

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Evonik expands capacity for customized Resomer powder biomaterials

New solvent-free micronization technology expanded at the Darmstadt site in Germany

New chemical method could cut waste from drug production

One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development

Bristol Myers Squibb and Cellares inks US$ 380 million capacity reservation for the manufacture of CAR T Cell Therapies

Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use

Cipla Health strengthens its play in beauty and personal care

CHL is strengthening its play in the fast-growing beauty and personal care sector

Evonik launches Botanicals & Natural Actives business segment

Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market

Healthcare Triangle partners with Cynomi to enhance cybersecurity in healthcare

Govt. announces the revamped pharmaceuticals technology upgradation assistance scheme

BlueRock Therapeutics Phase I clinical trial for Parkinson’s disease continues to show positive trends

Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months